Articles From: China's Wanda weighs deal for stake in Lions Gate to Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting


By Ben Fritz and Laurie Burkitt BEIJING -- China's Dalian Wanda Group Co.
Sign-up for China's Wanda weighs deal for stake in Lions Gate investment picks
2014/12/8
By Ben Fritz By Ben Fritz The hacking group calling itself Guardians of Peace continued its public attack on Sony Pictures Entertainment on Monday, saying it had released more internal data and demanding that the studio stop the upcoming release of its comedy "The Interview," according to a note that claims to be from the organization.
Sign-up for UPDATE: Email claims fresh Sony data released, threatens studio investment picks
By Ben Fritz Redbox is raising its DVD rental price by 25%, in a move that could improve the company's stagnant bottom line and help the Outerwall Inc. unit invest in new technology.
Sign-up for Redbox raising DVD rental price by 25% investment picks
By Ben Fritz Redbox is raising its DVD rental price by 25%, in a move that could improve the company's stagnant bottom line and help the Outerwall Inc. unit invest in new technology.
Sign-up for UPDATE: Redbox raising DVD rental price by 25% investment picks
2014/10/2
By Ben Fritz Robert Iger will stay on as chief executive and chairman of Walt Disney Co.
Sign-up for Disney extends CEO Iger's contract until 2018 investment picks
2014/10/2
By Ben Fritz Robert Iger will stay on as chief executive and chairman of Walt Disney Co.
Sign-up for UPDATE: Disney extends CEO Iger's contract until 2018 investment picks
2014/12/8
By Ben Fritz Sony Pictures seemed like a distant memory to Cassandra Sorrell.
Sign-up for Victims of Sony Breach Left Fuming investment picks
By Ben Fritz Walt Disney Co.
Sign-up for Apple, Google, set Disney video deal investment picks
By Ben Fritz Walt Disney Co.
Sign-up for Apple, Google set Disney video deal investment picks
2014/12/10
By Ben Otto JAKARTA, Indonesia--Indonesia's new economics minister said the government will take steps to create a more welcoming climate for investors by revamping contracts with oil-and-gas producers and reducing the legal uncertainty that has rocked companies such as Chevron Corp.
Sign-up for Indonesia Looks to Lure Investors -- Update investment picks
2014/12/9
By Ben Otto JAKARTA--Indonesia will revamp long-outdated oil and gas contracts, untangle legal problems that have hit companies like Chevron (CVX) and IM2, and create foreign-friendly incentives as it seeks to top 8% growth in the coming years, its chief economics minister says.
Sign-up for Indonesia to Push More Subsidy Reform, Resolve Legal Problems For Investors - Economy Minister investment picks
2014/10/27
http://media.marketwire.com/attachments/201404/237738_237722_JLLLogoFinalArtwork_RGB.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1153929&ProfileId=051205&sourceType=1 CHICAGO, IL --
Sign-up for Corporations Find Surprising Path to Business Productivity Through Real Estate Data investment picks
By Benjamin Pimentel, MarketWatch SAN FRANCISCO (MarketWatch)--Oracle Corp.
Sign-up for What to look for in Oracle's earnings report investment picks
By Benjamin Pimentel, MarketWatch SAN FRANCISCO (MarketWatch) -- Shares of Oracle Corp.
Sign-up for UPDATE: Oracle, Yahoo in focus after hours investment picks
By Benjamin Pimentel, MarketWatch SAN FRANCISCO (MarketWatch) -- Larry Ellison is stepping down as chief executive of Oracle Corp.
Sign-up for Larry Ellison guided Oracle through major shifts in IT investment picks
By Benjamin Pimentel, MarketWatch SAN FRANCISCO (MarketWatch)--Oracle Corp.
Sign-up for UPDATE: What to look for in Oracle's earnings report investment picks
By Benjamin Pimentel, MarketWatch SAN FRANCISCO (MarketWatch) -- Shares of Oracle Corp.
Sign-up for Oracle, Yahoo in focus after hours investment picks
2014/11/27
By Benoît Faucon, Summer Said, Sarah Kent and Nicole Lundeen VIENNA--OPEC members agreed on Thursday to stick to the oil-producer group's existing output target--a move that would require modest cuts in production but which stops well short of the stronger action some members had called for to bolster prices.
Sign-up for OPEC Leaves Production Target Unchanged -- Update investment picks
2014/11/26
By Benoit Faucon VIENNA--Iran's oil minister met BP PLC (BP) and Total SA (TOT) on Wednesday, in a sign of renewed interest for the country's oil sector.
Sign-up for Iranian Oil Minister Meets With BP, Total and Lukoil investment picks
2014/11/7
By Beth Baker First there were in-law apartments.
Sign-up for UPDATE: A backyard cottage for Mom and Dad investment picks
Marcus Theatres ® , a division of The Marcus Corporation (NYSE:MCS), is continuing its multi-million dollar investment in its circuit to bring consumers the ultimate movie-going experience.
Sign-up for Marcus Theatres® Continues to Invest in Creating the Ultimate Movie-Going Experience investment picks
2014/10/3
By Evelyn M.
Sign-up for Yahoo nears investment in Snapchat investment picks
2014/10/13
By Biman Mukherji and Ese Erhereine Asians buy most of the world's gold, but nearly all of it trades in London.
Sign-up for Asian market hubs move into gold investment picks
2014/12/1
By Biman Mukherji And Joyu Wang HONG KONG--For years, Wo Shing Goldsmith has warmly ushered in eager buyers from mainland China, with customer traffic peaking at year-end.
Sign-up for Hong Kong Gold Sales Fall as China Tackles Corruption investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) in patients with ipilimumab-refractory advanced melanoma (n=540). At six months, the PFS rates for KEYTRUDA were 34 percent at the 2 mg/kg dose (95% CI, 27-41) (n=180) and 38 percent at the 10 mg/kg dose (95% CI, 31-45) (n=181), compared to 16 percent for chemotherapy (95% CI, 10-22) (n=179). The median duration of follow-up at the interim analysis was 10 months.
Sign-up for Merck Announces Positive Study Investigating the Use of KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA ® (pembrolizumab) – the company’s anti-PD-1 therapy – in PD-L1 positive, advanced urothelial cancer (also known as bladder cancer). The early findings presented showed a confirmed overall response rate of 24 percent with KEYTRUDA as monotherapy, as measured by RECIST v1.1, central review (n= 7/29: 95% CI, 10.3-43.5) including a complete response rate of 10 percent (3/29). At the time of analysis, response durations ranged from 16+ to 40+ weeks with six of the seven responders continuing on therapy.
Sign-up for Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014 investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA ® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma Kinase (ALK) rearrangement-negative non-small cell lung cancer (NSCLC) whose disease has progressed on or following platinum-based chemotherapy.
Sign-up for Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA ® (pembrolizumab) – the company’s anti-PD-1 therapy – in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). These studies will be presented in oral sessions at the Society for Melanoma Research (SMR) 2014 International Congress, Nov.
Sign-up for New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA ® (pembrolizumab) – the company’s anti-PD-1 therapy – in PD-L1 positive, advanced gastric cancer.
Sign-up for Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014 investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA ® (pembrolizumab), the company’s anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin.
Sign-up for Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: China's Wanda weighs deal for stake in Lions Gate to Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent